Trial Profile

A registrational phase 3 trial of ceftibuten-ledaborbactam etzadroxil for complicated urinary tract infections

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2025 New trial record
14 Aug 2025 According to a Basilea Pharmaceutica media release, company expects to starting a registrational phase 3 program in cUTI in about 18 months.
14 Aug 2025 According to a Basilea Pharmaceutica media release, the company announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc. to acquire global rights to ceftibuten-ledaborbactam etzadroxil and initiate a Phase 3 registrational trial in complicated urinary tract infections (cUTI).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com